Key facts
- It has raised $5.8M; the latest was Seed Round ($5.8M) in Apr 2026.
- Notable investors include Inveready Asset Management, XesGalicia.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Iteria Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Iteria Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iteria Biopharma
Operator of a biopharmaceutical company intended to create chemical entities that modulate difficult oncology targets to treat cancers with unmet medical needs. The company offers innovative drug discovery through advanced medicinal chemistry, strong intellectual property protection and lean project management, enabling customers to access novel cancer therapies that are safer, more effective and designed to overcome the limitations of traditional treatments.
- Sector
- Healthcare
- HQ
- A Coruña, Spain
- Founded
- 2024
- Employees
- 5
- Website
- iteriabiopharma.com/
- Ownership
- Privately Held (backing)
Iteria Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iteria Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iteria Biopharma in its N-PORT filings yet. We sweep new filings monthly.